RT Journal Article
SR Electronic
T1 Potassium canrenoate compounding for administration via enteral feeding tubes: a physical and microbiological stability study
JF European Journal of Hospital Pharmacy
JO Eur J Hosp Pharm
FD British Medical Journal Publishing Group
SP ejhpharm-2017-001276
DO 10.1136/ejhpharm-2017-001276
A1 Serena Logrippo
A1 Matteo Sestili
A1 Roberta Ganzetti
A1 Giulia Bonacucina
A1 Antonella Marziali
A1 Patrizia Fattoretti
A1 Silvia Busco
A1 Alessandro Caraffa
A1 Carlo Polidori
A1 Giovanni Filippo Palmieri
YR 2017
UL http://ejhp.bmj.com/content/early/2017/08/04/ejhpharm-2017-001276.abstract
AB Background Swallowing difficulties are arising in an increasing number of patients, especially in elderly people. When deglutition ability is completely compromised, enteral administration of a drug via feeding tubes is used. Licensed pharmacists have to compound the original solid forms to enable this drug therapy.Objectives To evaluate the possibility of compounding original commercial tablets to produce a liquid formulation suitable for administering via a feeding tube.Methods Two liquid formulations containing potassium canrenoate 5 mg/mL were prepared: a standard solution obtained by solubilising raw material and an extemporaneous preparation obtained by dissolving film-coated 100 mg tablets. Spectrophotometric determinations (UV range) of the drug established chemical stability of the analyte up to 60 days. Samples were tested for microbial growth. Gravimetric quantifications of liquid formulations were used to check any weight loss during the different steps before enteral administration.Results UV data confirmed the chemical stability of potassium canrenoate up to 60 days. Samples showed no microbial growth. A higher weight loss was recorded in extemporaneous preparations than in the standard solution (10.7% vs 7.6%) according to the gravimetric quantification.Conclusion It is possible to compound the original tablets into a liquid formulation suitable for administration via a feeding tube.